Tenax Therapeutics, Inc. (TENX): Price and Financial Metrics


Tenax Therapeutics, Inc. (TENX): $0.32

0.02 (+6.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TENX Stock Price Chart Interactive Chart >

Price chart for TENX

TENX Price/Volume Stats

Current price $0.32 52-week high $2.06
Prev. close $0.30 52-week low $0.23
Day low $0.29 Volume 245,800
Day high $0.33 Avg. volume 142,034
50-day MA $0.59 Dividend yield N/A
200-day MA $0.94 Market Cap 8.02M

Tenax Therapeutics, Inc. (TENX) Company Bio


Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. The company was founded in 1967 and is based in Morrisville, North Carolina.


TENX Latest News Stream


Event/Time News Detail
Loading, please wait...

TENX Latest Social Stream


Loading social stream, please wait...

View Full TENX Social Stream

Latest TENX News From Around the Web

Below are the latest news stories about Tenax Therapeutics Inc that investors may wish to consider to help them evaluate TENX as an investment opportunity.

Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

MORRISVILLE, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that Tenax Therapeutics appointed Robyn Hunter to its Board of Directors, effective January 28, 2022. Ms. Hunter is an independent director and will chair the Board’s audit and compliance committee. “We are ve

Yahoo | January 31, 2022

Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjects with Any Health Condition Patent Term to 2039, Exclusive of Any Possible Extensions MORRISVILLE, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ: TENX ), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the company''s subcutaneous formulation of levosimendan, TNX-102, which is currently being developed for the treatment of pulmonary hypertension associated with left heart failure (PH-HFpEF). On January 4, 2022, Tenax Therapeutics was issued US Pat. No. 11,2...

Benzinga | January 12, 2022

Tenax Therapeutics nabs new U.S. patent for the subcutaneous use of levosimendan

Tenax Therapeutics (TENX) announces that the USPTO has granted a patent for the companys subcutaneous formulation of levosimendan, TNX-102, which is currently being developed for

Seeking Alpha | January 12, 2022

TENX: TNX-103 & TNX-201 Near Ready for Phase III

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Clinical Program Update On January 4, 2022, Tenax Therapeutics, Inc. (NASDAQ:TENX) provided an update on TNX-102 (subcutaneous levosimendan), TNX-103 (oral levosimendan) and TNX-201 (enteric-coated imatinib in PAH). Tenax has received a Notice of Allowance from the USPTO 1 for subcutaneous administration of levosimendan

Yahoo | January 5, 2022

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

Receives a Notice of Allowance of Multiple Patent Claims for TNX-102 (subcutaneous levosimendan) Successfully Completes IV to Oral Transition Substudy for TNX-103 (oral levosimendan) Plans to Initiate Phase 3 Study of TNX-201 (oral imatinib mesylate) in Pulmonary Arterial Hypertension in 2H 2022 Forms Scientific Advisory Board with Expertise in Pulmonary Vascular Disease MORRISVILLE, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical compa

Yahoo | January 4, 2022

Read More 'TENX' Stories Here

TENX Price Returns

1-mo -50.39%
3-mo -58.71%
6-mo -68.32%
1-year -83.76%
3-year -76.38%
5-year -97.68%
YTD -69.23%
2021 -44.09%
2020 31.91%
2019 16.53%
2018 -87.65%
2017 -74.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.427 seconds.